Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 4 of 93« First...23456...102030...Last »

Recent Study Suggests Diabetes Treatment May Have Potential in Parkinson’s Disease

Research published in the journal Nature by researchers at the National Health Research Institutes in Taiwan and the National Institute on Aging, National Institutes of Health in the U.S. suggest that a class of diabetes medications known as GLP-1 analogs may be effective treatments for Parkinson’s disease.

Read More »

Sienna Biopharma acne treatment fails two studies

Sienna Biopharmaceuticals Inc.’s lead experimental acne treatment failed to meet the main goals of two pivotal trials and that the chances of it clearing a third study appeared weaker.

Read More »

RedHill has positive results from Crohn’s disease trial

RedHill Biopharma reported positive safety and efficacy results from a late-stage clinical trial for the Israeli company’s treatment for Crohn’s disease called RHB-104.

Read More »

Tonix Pharma Halts Phase III Trial for PTSD

Tonix Pharmaceuticals Inc. halted the company’s Phase III HONOR clinical trial of Tonmya (cyclobenzaprine HCL sublingual tablets) in military-related post-traumatic stress disorder.

Read More »

Investors turn wary on Biogen/Eisai Alzheimer’s drug results

Shares of Eisai Co. Ltd. plunged as much as 21 percent after the results of the company’s experimental Alzheimer’s drug being developed with partner Biogen Inc. failed to enthuse investors.

Read More »

Mediterranean diet might help ease psoriasis

The Mediterranean diet might do more than help ward off heart disease, it may also help improve psoriasis, a new study suggests.

Read More »

Allergan, Molecular Partners eye drug abicipar meets main goal in two studies

Allergan and Molecular Partners’ drug for neovascular age-related macular degeneration met the main goal in two late-stage studies.

Read More »

Pfizer-Lilly pain drug meets late-stage trial goals

An experimental osteoarthritis drug developed by Pfizer Inc. and Eli Lilly and Co. achieved its main goal of lowering pain in a late-stage clinical trial.

Read More »

Bill Gates backs $30 million push for early Alzheimer’s diagnostics

Billionaire Bill Gates and Estée Lauder Cos chairman emeritus Leonard Lauder said they will award $30 million over three years to encourage development of new tests for early detection of Alzheimer’s disease.

Read More »

Roche touts new flu drug

Roche’s hopes of recapturing lost ground in the generics-flooded influenza market got a boost after a late-stage study showed the Swiss drugmaker’s new medicine reduced symptoms in people at high risk of complications.

Read More »

Zogenix’s seizure drug clears late-stage trial

Zogenix Inc.’s drug to treat a rare form of childhood epilepsy reduced convulsive seizures in a second late-stage trial, sending the drug developer’s shares up as much as 26 percent.

Read More »

AbbVie Stock Drops After Disappointing Clinical Trial Update

AbbVie’s shares dropped after releasing an update on the company’s Phase III B-cell lymphoma trial.

Read More »

Israeli firm gets U.S. nod for advanced trials for non-opiate painkiller

PainReform received FDA clearance to begin late-stage studies for a pain-relief drug that is a departure from opiate-based narcotics.

Read More »

Celgene and Acceleron’s Luspatercept Hits Primary Endpoints in Beta-Thalassemia Trial

Celgene Corporation and Acceleron Pharma Inc. indicated the companies’ Phase III clinical trial of luspatercept in beta-thalassemia hit its primary endpoint of erythroid response.

Read More »

CTI BioPharma’s cancer drug fails late-stage trial, shares tumble

CTI BioPharma Corp.’s treatment for a type of blood cancer did not meet the main goal of a late-stage trial, sending the company’s shares down 17 percent.

Read More »

Biogen, Eisai’s AD succeeds in mid-stage study

Japanese drugmaker Eisai Co. and Biogen Inc. said the final analysis of a mid-stage trial of their Alzheimer’s drug showed positive results for patients who received the highest dose.

Read More »

Sanofi beefing up diabetes pipeline, sees growth returning

Sanofi sees a more diversified pipeline driving a return to growth at the company’s diabetes unit in the coming years and will consider acquisitions and partnerships to help boost performance.

Read More »

Lilly’s Taltz Hits Endpoints in AS Study

Eli Lilly announced the results of the company’s COAST-W Phase III clinical trial of Taltz (ixekizumab) to treat ankylosing spondylitis. The study met both primary and major secondary endpoints.

Read More »

GBT’s sickle cell disease drug meets trial goal

Global Blood Therapeutics’ sickle cell disease treatment met the main goal of a late-stage trial, but there is scepticism over whether the drug would get an accelerated review from health regulators.

Read More »

Summit’s muscle-wasting disorder drug fails study

Britain’s Summit Therapeutics will stop developing the company’s Duchenne muscular dystrophy drug after ezutromid failed a mid-stage study, wiping out nearly 80 percent of its market value.

Read More »

Page 4 of 93« First...23456...102030...Last »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2018 Focus: Top 200 Meds, Year After Launch, VR/AR and more!


Ad Right Bottom